Progress in Research and Application of CAR-T Cell Therapy in T-Lymphocyte Tumors --Review.
10.19746/j.cnki.issn.1009-2137.2023.06.046
- Author:
Fan GAO
1
;
Min YU
1
;
Fei LI
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanchang University.
- Publication Type:Journal Article
- Keywords:
CAR-T cell therapy;
T-lymphocyte tumors;
challenge;
progress
- MeSH:
Humans;
T-Lymphocytes;
Receptors, Chimeric Antigen/metabolism*;
Neoplasms/metabolism*;
Immunotherapy, Adoptive/methods*;
Cell- and Tissue-Based Therapy
- From:
Journal of Experimental Hematology
2023;31(6):1894-1898
- CountryChina
- Language:Chinese
-
Abstract:
T-lymphocyte tumors are a group of diseases containing various types of lymphatic system tumors, with strong heterogeneity and poor clinical outcomes. Chimeric antigen receptor T (CAR-T) cell therapy, as a new immune cell therapy, has made a breakthrough in the field of B-lymphocyte tumors. People are interested in the application prospect of this technique in the field of T-lymphocyte tumors. Some studies have shown that CAR-T cell therapy has made some progress in the treatment of T-lymphocyte tumors, and CAR-T for some targets has entered the stage of clinical trials. However, due to the characteristics of T cells, there are also many challenges. This article reviews the research and application of CAR-T cell therapy in T-lymphocyte tumors.
